
Stephanie G C Kroeze

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3038084/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treatment Reviews, 2017, 53, 25-37.	7.7	169
2	Examining the â€~gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU International, 2012, 110, 1595-1601.	2.5	111
3	Assessment of Laparoscopic Suturing Skills of Urology Residents: A Pan-European Study. European Urology, 2009, 56, 865-873.	1.9	56
4	Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 889-900.	6.4	44
5	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	2.7	34
6	Prostate-specific Membrane Antigen Positron Emission Tomography–detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	3.1	34
7	Real-Time 3D Fluoroscopy-Guided Large Core Needle Biopsy of Renal Masses: A Critical Early Evaluation According to the IDEAL Recommendations. CardioVascular and Interventional Radiology, 2012, 35, 680-685.	2.0	32
8	Impact of comorbidity on complications after nephrectomy: use of the Clavien Classification of Surgical Complications. BJU International, 2012, 110, 682-687.	2.5	32
9	Repeated Courses of Radiosurgery for New Brain Metastases to Defer Whole Brain Radiotherapy: Feasibility and Outcome With Validation of the New Prognostic Metric Brain Metastasis Velocity. Frontiers in Oncology, 2018, 8, 551.	2.8	32
10	Incomplete thermal ablation stimulates proliferation of residual renal carcinoma cells in a translational murine model. BJU International, 2012, 110, E281-6.	2.5	31
11	Intratumoral Administration of Holmium-166 Acetylacetonate Microspheres: Antitumor Efficacy and Feasibility of Multimodality Imaging in Renal Cancer. PLoS ONE, 2013, 8, e52178.	2.5	29
12	Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. European Journal of Cancer, 2010, 46, 3375-3382.	2.8	28
13	The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World Journal of Urology, 2015, 33, 881-887.	2.2	20
14	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	2.6	20
15	Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU International, 2021, 127, 703-711.	2.5	20
16	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the â€TOaSTT' database. Radiation Oncology, 2021, 16, 4.	2.7	20
17	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. World Journal of Urology, 2019, 37, 457-467.	2.2	19
18	Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. Strahlentherapie Und Onkologie, 2019, 195, 199-206.	2.0	19

STEPHANIE G C KROEZE

#	Article	IF	CITATIONS
19	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	6.4	13
20	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	2.8	11
21	Photodynamic Therapy as Novel Nephron Sparing Treatment Option for Small Renal Masses. Journal of Urology, 2012, 187, 289-295.	0.4	9
22	Radio Frequency Ablation Combined with Interleukin-2 Induces an Antitumor Immune Response to Renal Cell Carcinoma in a Murine Model. Journal of Urology, 2012, 188, 607-614.	0.4	9
23	Outcomes of adolescents and young adults treated for brain and skull base tumors with pencil beam scanning proton therapy. Pediatric Blood and Cancer, 2020, 67, e28664.	1.5	8
24	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. Radiation Oncology, 2020, 15, 135.	2.7	8
25	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. Cancers, 2021, 13, 4780.	3.7	8
26	True abscopal effect in a patient with metastatic non-small cell lung cancer. Radiation Oncology, 2021, 16, 194.	2.7	8
27	Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database. Radiation Oncology, 2018, 13, 113.	2.7	6
28	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. Melanoma Research, 2020, 30, 552-561.	1.2	5
29	A Prospective Study on Health-Related Quality of Life and Patient-Reported Outcomes in Adult Brain Tumor Patients Treated with Pencil Beam Scanning Proton Therapy. Cancers, 2021, 13, 4892.	3.7	3
30	2084 HAS MODERN TURP EVOLVED OVER THREE DECADES?: A COMPARATIVE ANALYSIS. Journal of Urology, 2010, 183, .	0.4	0
31	72 INTRATUMORAL ADMINISTRATION OF HOLMIUM LOADED MICROSPHERES AS A NOVEL MINIMALLY INVASIVE THERAPY FOR KIDNEY CANCER; AN ANIMAL STUDY. Journal of Urology, 2010, 183, .	0.4	0
32	86 TOWARDS PHOTODYNAMIC THERAPY AS NOVEL MINIMALLY INVASIVE TREATMENT FOR RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.4	0
33	383 RADIOFREQUENCY ABLATION COMBINED WITH INTERLEUKIN-2 PREVENTS METASTASIS FORMATION IN MOUSE RENAL CELL CARCINOMA. Journal of Urology, 2011, 185, .	0.4	0
34	531 THE IMPACT OF COMORBIDITY ON COMPLICATIONS FOLLOWING NEPHRECTOMY. Journal of Urology, 2011, 185, .	0.4	0
35	294 INCOMPLETE THERMAL ABLATION INDUCES INCREASED PROLIFERATION OF RENAL CARCINOMA CELLS IN A MURINE MODEL. Journal of Urology, 2012, 187, .	0.4	0
36	1198 CLINICAL EFFICACY OF MULTIPOLAR RADIOFREQUENCY ABLATION OF SMALL RENAL MASSES: A TREAT-AND-RESECT STUDY. Journal of Urology, 2013, 189, .	0.4	0

STEPHANIE G C KROEZE

#	Article	IF	CITATIONS
37	1833 THE BLIND SPOTS IN FOLLOW-UP AFTER NEPHRECTOMY FOR LOCALISED RENAL CELL CARCINOMA. Journal of Urology, 2013, 189, .	0.4	0
38	EP-1414: Toxicity of concurrent stereotactic radiotherapy and targeted or immunotherapy: a systematic review. Radiotherapy and Oncology, 2017, 123, S756.	0.6	0
39	EP-1550: Radiotherapy of PSMA-positive oligometastatic recurrent prostate cancer: a single-center experience. Radiotherapy and Oncology, 2018, 127, S836.	0.6	0
40	OC-0163 Risk classification for PSA relapse after PSMAPET-guided RT for oligorecurrent prostate cancer. Radiotherapy and Oncology, 2019, 133, S79-S80.	0.6	0
41	OC-0166 Cumulative metastases volume, not number of brain metastases predicts survival in melanoma patients. Radiotherapy and Oncology, 2019, 133, S81-S82.	0.6	0
42	EP-1563 PSMA-ligand based radiotherapy for lymph node relapsed prostate cancer after radical prostatectomy. Radiotherapy and Oncology, 2019, 133, S843-S844.	0.6	0
43	OC-0059 Stereotactic radiotherapy for oligoprogressive NSCLC: clinical scenarios affecting survival. Radiotherapy and Oncology, 2019, 133, S23-S24.	0.6	0
44	RONC-15. OUTCOMES OF BRAIN AND SKULL-BASE TUMOURS IN ADOLESCENTS AND YOUNG ADULTS TREATED WITH PENCIL BEAM SCANNING PROTON THERAPY. Neuro-Oncology, 2020, 22, iii458-iii458.	1.2	0
45	PO-1169: Influence of localisation of PSMA-positive oligo-metastases on efficacy of metastasis-directed EBRT. Radiotherapy and Oncology, 2020, 152, S615.	0.6	0
46	OC-0453: Efficacy and safety of stereotactic radiotherapy combined with TKIs for metastatic lesions Radiotherapy and Oncology, 2020, 152, S251.	0.6	0